Type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): Role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs

Chemico-Biological Interactions

Volumn 178, Issue 1-3, 2009, Pages 221-227

  Byrns, Michael C ^a   Penning, Trevor M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Aldo keto reductase; Indomethacin; N Phenylanthranilic acids; Prostaglandin metabolism; Steroid hormone metabolism

Indexed keywords

ACETYLSALICYLIC ACID; EFENAMIC ACID; ESTRADIOL; FLURBIPROFEN; IBUPROFEN; INDOLEACETIC ACID; INDOMETACIN; MECLOFENAMIC ACID; MELATONIN DERIVATIVE; N (4 CHLOROBENZOYL)MELATONIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROGESTERONE; PROSTAGLANDIN; PROSTAGLANDIN F; PROSTANOID RECEPTOR; SALICYLIC ACID; STEROID; SULINDAC; TESTOSTERONE 17BETA DEHYDROGENASE; UNCLASSIFIED DRUG; ZOMEPIRAC; 15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; 3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; AKR1C3 PROTEIN, HUMAN; ENZYME INHIBITOR;

ARTICLE; BREAST CANCER; BREAST CELL; CELL PROLIFERATION; CHEMICAL REACTION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG INHIBITION; EPIMER; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PROTEIN EXPRESSION; RADIOCHROMATOGRAPHY; SIGNAL TRANSDUCTION; BIOCATALYSIS; BREAST TUMOR; DRUG ANTAGONISM; ENZYMOLOGY; METABOLISM; TUMOR CELL LINE;

3-HYDROXYSTEROID DEHYDROGENASES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOCATALYSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME INHIBITORS; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES;

EID: 59049089110     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2008.10.024     Document Type: Article

References (32)

1. Labrie F., Luu-The V., Lin S.X., Simard J., Labrie C., El Alfy M., Pelletier G., and Belanger A. Intracrinology: role of the family of 17β-hydroxysteroid dehydrogenases in human physiology and disease. J. Mol. Endocrinol. 25 (2000) 1-16
2. Suzuki T., Miki Y., Nakamura Y., Moriya T., Ito K., Ohuchi N., and Sasano H. Sex steroid-producing enzymes in human breast cancer. Endocr. Relat. Cancer 12 (2005) 701-720
3. Penning T.M., Burczynski M.E., Jez J.M., Hung C.F., Lin H.K., Ma H., Moore M., Palackal N., and Ratnam K. Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem. J. 351 (2000) 67-77
4. Dufort I., Rheault P., Huang X.F., Soucy P., and Luu-The V. Characteristics of a highly labile human type 5 17β-hydroxysteroid dehydrogenase. Endocrinology 140 (1999) 568-574
5. Sharma K.K., Lindqvist A., Zhou X.J., Auchus R.J., Penning T.M., and Andersson S. Deoxycorticosterone inactivation by AKR1C3 in human mineralocorticoid target tissues. Mol. Cell Endocrinol. 248 (2006) 79-86
6. Carnevale R.P., Proietti C.J., Salatino M., Urtreger A., Peluffo G., Edwards D.P., Boonyaratanakornkit V., Charreau E.H., Bal de Kier J.E., Schillaci R., and Elizalde P.V. Progestin effects on breast cancer cell proliferation, proteases activation, and in vivo development of metastatic phenotype all depend on progesterone receptor capacity to activate cytoplasmic signaling pathways. Mol. Endocrinol. 21 (2007) 1335-1358
7. Hardy D.B., Janowski B.A., Chen C.C., and Mendelson C.R. Progesterone receptor inhibits aromatase and inflammatory response pathways in breast cancer cells via ligand-dependent and ligand-independent mechanisms. Mol. Endocrinol. 22 (2008) 1812-1824
8. 2 11-ketoreductase activity. J. Biochem. (Tokyo) 124 (1998) 940-946
9. Suzuki-Yamamoto T., Nishizawa M., Fukui M., Okuda-Ashitaka E., Nakajima T., Ito S.K., and Watanabe K. cDNA cloning, expression and characterization of human prostaglandin F synthase. FEBS Lett. 462 (1999) 335-340
10. 2α receptor in human endometrial adenocarcinoma: regulation of proliferation by activation of the epidermal growth factor receptor and mitogen-activated protein kinase signaling pathways. J. Clin. Endocrinol. Metab. 89 (2004) 986-993
11. Shiraki T., Kamiya N., Shiki S., Kodama T.S., Kakizuka A., and Jingami H. α,β-Unsaturated ketone is a core moiety of natural ligands for covalent binding to peroxisome proliferator-activated receptor γ. J. Biol. Chem. 280 (2005) 14145-14153
12. 2 inhibits multiple steps in the NF-κB signaling pathway. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 4844-4849
13. 2 inhibits transcriptional activity of estrogen receptor-α via covalent modification of DNA-binding domain. Cancer Res. 67 (2007) 2595-2602
14. 2 formation and progesterone elimination in MCF-7 breast cancer cells and promotes estrogen-dependent cell proliferation 16 June 2008, The Endocrine Society's 90th Annual Meeting, abstract # P2-43.
15. Bauman D.R., Rudnick S.I., Szewczuk L.M., Jin Y., Gopishetty S., and Penning T.M. Development of nonsteroidal anti-inflammatory drug analogs and steroid carboxylates selective for human aldo-keto reductase isoforms: potential antineoplastic agents that work independently of cyclooxygenase isozymes. Mol. Pharmacol. 67 (2005) 60-68
16. Byrns M.C., Steckelbroeck S., and Penning T.M. An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3α-HSD, type 5 17β-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies. Biochem. Pharmacol. 75 (2008) 484-493
17. Lin H.K., Steckelbroeck S., Fung K.M., Jones A.N., and Penning T.M. Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3α-hydroxysteroid dehydrogenase/type 5 17β-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate. Steroids 69 (2004) 795-801
18. Shibuya R., Suzuki T., Miki Y., Yoshida K., Moriya T., Ono K., Akahira J., Ishida T., Hirakawa H., Evans D.B., and Sasano H. Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast. Endocr. Relat. Cancer 15 (2008) 113-124
19. Oduwole O.O., Li Y., Isomaa V.V., Mantyniemi A., Pulkka A.E., Soini Y., and Vihko P.T. 17β-hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer. Cancer Res. 64 (2004) 7604-7609
20. Jansson A.K., Gunnarsson C., Cohen M., Sivik T., and Stal O. 17β-hydroxysteroid dehydrogenase 14 affects estradiol levels in breast cancer cells and is a prognostic marker in estrogen receptor-positive breast cancer. Cancer Res. 66 (2006) 11471-11477
21. Lee S.H., Rangiah K., Williams M.V., Wehr A.Y., DuBois R.N., and Blair I.A. Cyclooxygenase-2-mediated metabolism of arachidonic acid to 15-oxo-eicosatetraenoic acid by rat intestinal epithelial cells. Chem. Res. Toxicol. 20 (2007) 1665-1675
22. Penning T.M., and Talalay P. Inhibition of a major NAD(P)-linked oxidoreductase from rat liver cytosol by steroidal and nonsteroidal anti-inflammatory agents and by prostaglandins. Proc. Natl. Acad. Sci. U.S.A. 80 (1983) 4504-4508
23. 2 11-ketoreductase (AKR1C3) in complex with the nonsteroidal anti-inflammatory drugs flufenamic acid and indomethacin. Cancer Res. 64 (2004) 1802-1810
24. 2 synthases by salicylate is dependent on the oxidative state of the enzymes. Adv. Exp. Med. Biol. 525 (2003) 125-128
25. Dhagat U., Carbone V., Chung R.P., Matsunaga T., Endo S., Hara A., and El Kabbani O. A salicylic acid-based analogue discovered from virtual screening as a potent inhibitor of human 20α-hydroxysteroid dehydrogenase. Med. Chem. 3 (2007) 546-550
26. Prusakiewicz J.J., Felts A.S., Mackenzie B.S., and Marnett L.J. Molecular basis of the time-dependent inhibition of cyclooxygenases by indomethacin. Biochemistry 43 (2004) 15439-15445
27. Kalgutkar A.S., Crews B.C., Rowlinson S.W., Marnett A.B., Kozak K.R., Remmel R.P., and Marnett L.J. Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 925-930
28. Kalgutkar A.S., Marnett A.B., Crews B.C., Remmel R.P., and Marnett L.J. Ester and amide derivatives of the nonsteroidal antiinflammatory drug, indomethacin, as selective cyclooxygenase-2 inhibitors. J. Med. Chem. 43 (2000) 2860-2870
29. Kalgutkar A.S., Crews B.C., Saleh S., Prudhomme D., and Marnett L.J. Indolyl esters and amides related to indomethacin are selective COX-2 inhibitors. Bioorg. Med. Chem. 13 (2005) 6810-6822
30. Arun B., and Goss P. The role of COX-2 inhibition in breast cancer treatment and prevention. Semin. Oncol. 31 (2004) 22-29
31. Su B., Diaz-Cruz E.S., Landini S., and Brueggemeier R.W. Suppression of aromatase in human breast cells by a cyclooxygenase-2 inhibitor and its analog involves multiple mechanisms independent of cyclooxygenase-2 inhibition. Steroids 73 (2008) 104-111
32. Bauman D.R., Steckelbroeck S., and Penning T.M. The roles of aldo-keto reductases in steroid hormone action. Drug News Perspect. 17 (2004) 563-578